QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
NASDAQ:BDTX

Black Diamond Therapeutics Stock Forecast, Price & News

$6.18
+0.30 (+5.10%)
(As of 12/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.98
$6.36
50-Day Range
$5.88
$9.06
52-Week Range
$5.81
$37.76
Volume
157,645 shs
Average Volume
454,016 shs
Market Capitalization
$223.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.49
30 days | 90 days | 365 days | Advanced Chart
Receive BDTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Black Diamond Therapeutics logo

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth factor receptor (EGFR), the tyrosine-protein kinase, or human epidermal growth factor receptor 2. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including allosteric and canonical EGFR mutations; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BDTX
Fax
N/A
Employees
73
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$6.04 per share

Profitability

Net Income
$-67.25 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
34,352,000
Market Cap
$223.90 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/08/2021
Today
12/07/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/24/2022

MarketRank

Overall MarketRank

1.81 out of 5 stars

Medical Sector

704th out of 1,394 stocks

Biological Products, Except Diagnostic Industry

110th out of 202 stocks

Analyst Opinion: 3.4Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Black Diamond Therapeutics (NASDAQ:BDTX) Frequently Asked Questions

Is Black Diamond Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Black Diamond Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Black Diamond Therapeutics stock.
View analyst ratings for Black Diamond Therapeutics
or view top-rated stocks.

How has Black Diamond Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Black Diamond Therapeutics' stock was trading at $22.65 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BDTX stock has decreased by 72.7% and is now trading at $6.18.
View which stocks have been most impacted by COVID-19
.

When is Black Diamond Therapeutics' next earnings date?

Black Diamond Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Black Diamond Therapeutics
.

How were Black Diamond Therapeutics' earnings last quarter?

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) announced its earnings results on Monday, November, 8th. The company reported ($0.97) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.98) by $0.01.
View Black Diamond Therapeutics' earnings history
.

What price target have analysts set for BDTX?

5 brokers have issued 1 year target prices for Black Diamond Therapeutics' stock. Their forecasts range from $10.00 to $53.00. On average, they anticipate Black Diamond Therapeutics' share price to reach $33.80 in the next year. This suggests a possible upside of 446.9% from the stock's current price.
View analysts' price targets for Black Diamond Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Black Diamond Therapeutics' key executives?

Black Diamond Therapeutics' management team includes the following people:
  • Dr. David M. Epstein, Co-Founder, Pres, CEO & Director (Age 62, Pay $837.79k)
  • Mr. Brent Hatzis-Schoch Esq., J.D., COO & Gen. Counsel (Age 56, Pay $670.23k) (LinkedIn Profile)
  • Dr. Rachel Wallach Humphrey, Chief Medical Officer (Age 60, Pay $228.89k)
  • Mr. Thomas Leggett, Chief Financial Officer (Age 44)
  • Dr. Christopher D. Roberts, Chief Scientific Officer (Age 51) (LinkedIn Profile)
  • Dr. Elizabeth Buck Ph.D., Exec. VP of Discovery & Translational Services (Age 46)
  • Dr. Karsten Witt, Sr. VP of Non-Clinical Devel. (Age 64)
  • Mr. Tai-An Lin Ph.D., VP & Head of Biology
  • Mr. Fang Ni Pharm.D., Chief Bus. Officer

What other stocks do shareholders of Black Diamond Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Black Diamond Therapeutics investors own include Alector (ALEC), Alteryx (AYX), Editas Medicine (EDIT), Gossamer Bio (GOSS), Micron Technology (MU), NVIDIA (NVDA), Homology Medicines (FIXX), II-VI (IIVI), Intel (INTC) and Invitae (NVTA).

When did Black Diamond Therapeutics IPO?

(BDTX) raised $151 million in an initial public offering (IPO) on Thursday, January 30th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Black Diamond Therapeutics' stock symbol?

Black Diamond Therapeutics trades on the NASDAQ under the ticker symbol "BDTX."

Who are Black Diamond Therapeutics' major shareholders?

Black Diamond Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.05%), Morgan Stanley (2.10%), Deerfield Management Company L.P. Series C (2.10%), Geode Capital Management LLC (0.97%), Two Sigma Investments LP (0.82%) and SG Americas Securities LLC (0.75%). Company insiders that own Black Diamond Therapeutics stock include Bradley J Phd Bolzon, Brent Hatzis-Schoch, Christopher D Roberts, David M Epstein, James E Flynn, Rajeev M Shah, Robert Alexander Ingram, Thomas Leggett and Versant Venture Capital Vi, L.
View institutional ownership trends for Black Diamond Therapeutics
.

Which major investors are selling Black Diamond Therapeutics stock?

BDTX stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, Two Sigma Investments LP, Deutsche Bank AG, Millennium Management LLC, Goldman Sachs Group Inc., Cubist Systematic Strategies LLC, Bank Julius Baer & Co. Ltd Zurich, and SG Americas Securities LLC. Company insiders that have sold Black Diamond Therapeutics company stock in the last year include Brent Hatzis-Schoch, Christopher D Roberts, and Thomas Leggett.
View insider buying and selling activity for Black Diamond Therapeutics
or view top insider-selling stocks.

Which major investors are buying Black Diamond Therapeutics stock?

BDTX stock was bought by a variety of institutional investors in the last quarter, including BioImpact Capital LLC, Morgan Stanley, Healthcare of Ontario Pension Plan Trust Fund, Two Sigma Advisers LP, Credit Suisse AG, BlackRock Inc., Squarepoint Ops LLC, and Bank of New York Mellon Corp. Company insiders that have bought Black Diamond Therapeutics stock in the last two years include James E Flynn, Rajeev M Shah, Robert Alexander Ingram, and Versant Venture Capital Vi, L.
View insider buying and selling activity for Black Diamond Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Black Diamond Therapeutics?

Shares of BDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Black Diamond Therapeutics' stock price today?

One share of BDTX stock can currently be purchased for approximately $6.18.

How much money does Black Diamond Therapeutics make?

Black Diamond Therapeutics has a market capitalization of $223.90 million. The company earns $-67.25 million in net income (profit) each year or ($3.39) on an earnings per share basis.

How many employees does Black Diamond Therapeutics have?

Black Diamond Therapeutics employs 73 workers across the globe.

What is Black Diamond Therapeutics' official website?

The official website for Black Diamond Therapeutics is www. blackdiamondtherapeutics.com.

Where are Black Diamond Therapeutics' headquarters?

Black Diamond Therapeutics is headquartered at 139 MAIN STREET, CAMBRIDGE MA, 02142.

How can I contact Black Diamond Therapeutics?

Black Diamond Therapeutics' mailing address is 139 MAIN STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-252-0848 or via email at [email protected].


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.